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Abstract
Background: Integrins are important adhesion molecules that regulate tumor and endothelial cell
survival, proliferation and migration. The integrin α5β1 has been shown to play a critical role during
angiogenesis. An inhibitor of this integrin, volociximab (M200), inhibits endothelial cell growth and
movement in vitro, independent of the growth factor milieu, and inhibits tumor growth in vivo in the
rabbit VX2 carcinoma model. Although volociximab has already been tested in open label, pilot
phase II clinical trials in melanoma, pancreatic and renal cell cancer, evaluation of the mechanism of
action of volociximab has been limited because this antibody does not cross-react with murine
α5β1, precluding its use in standard mouse xenograft models.
Methods: We generated a panel of rat-anti-mouse α5β1 antibodies, with the intent of identifying
an antibody that recapitulated the properties of volociximab. Hybridoma clones were screened for
analogous function to volociximab, including specificity for α5β1 heterodimer and blocking of
integrin binding to fibronectin. A subset of antibodies that met these criteria were further
characterized for their capacities to bind to mouse endothelial cells, inhibit cell migration and block
angiogenesis in vitro. One antibody that encompassed all of these attributes, 339.1, was selected
from this panel and tested in xenograft models.
Results:  A panel of antibodies was characterized for specificity and potency. The affinity of
antibody 339.1 for mouse integrin α5β1 was determined to be 0.59 nM, as measured by BIAcore.
This antibody does not significantly cross-react with human integrin, however 339.1 inhibits murine
endothelial cell migration and tube formation and elicits cell death in these cells (EC50 = 5.3 nM). In
multiple xenograft models, 339.1 inhibited the growth of established tumors by 40–60% (p < 0.05)
and this inhibition correlates with a concomitant decrease in vessel density.
Conclusion: The results herein demonstrate that 339.1, like volociximab, exhibits potent anti-
α5β1 activity and confirms that inhibition of integrin α5β1 impedes angiogenesis and slows tumor
growth in vivo.
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Background
Angiogenesis is the process by which nascent blood ves-
sels form from existing vasculature to supply new tissue
with nutrients. This process was proposed by Folkman
over three decades ago to drive tumor growth beyond a
few millimeters [1,2]. Since that time, numerous angio-
genesis inhibitors have been shown to inhibit vessel
growth in models of neovascularization and restrict the
growth of tumors in pre-clinical models of cancer. Cur-
rently, anti-angiogenic agents that are approved for the
treatment of cancer include sunitinib [3,4], sorafenib
[5,6] and bevacizumab [7,8], and many others are in late
stage clinical testing.
Tumors secrete multiple growth factors that drive activa-
tion, migration and proliferation of vascular endothelial
cells (EC's), including TGF-α, bFGF and VEGF [9]. These
agents bind their respective receptors on EC's to initiate
signaling cascades that culminate in pro-angiogenic
events. To date, the majority of angiogenesis inhibitors
have focused on disrupting growth factor signalling,
including the aforementioned clinically approved agents,
which primarily target the VEGF axis [4,5,8]. However,
growth factors are not the only pro-angiogenic molecules
that influence the tumor microenvironment. For example,
tumor cells and tumor-associated macrophages are
known to secrete matrix metalloproteinases, such as
MMP-9 and MMP-2 [10]. These enzymes degrade the
basement membrane, exposing components of the extra-
cellular matrix, including fibronectin. These exposed ECM
proteins drive angiogenesis by ligating integrins, which
play a central role in the angiogenic program [11-14].
Integrins are heterodimeric signalling and adhesion mol-
ecules consisting of an alpha chain and a beta chain. Lig-
ands for these receptors bind integrins and induce EC
shape change, motility and growth [12,14]. One well-
characterized example of an integrin-ECM interaction is
that between fibronectin and integrin α5β1, an integrin
that is up-regulated in proliferating EC's [15,16]. Ligation
of α5β1 has been shown to promote cell survival through
Bcl-2, migration through RhoA and proliferation through
ERK, Akt and FAK-dependent mechanisms [13,15-20].
Activation of these and other cellular programs through
integrin α5β1 in endothelial cells results in angiogenesis.
Conversely, blockade of α5β1 ligation has been demon-
strated to inhibit angiogenesis, at least in part through the
inhibition of signalling and the induction of the cell death
program through caspases [15-21].
Volociximab is a chimeric, function blocking antibody
that targets integrin α5β1. We have previously shown that
this antibody elicits cell death in dividing endothelial
cells, inhibits angiogenesis in a cynomolgus monkey
model of choroidal neovascularization [21] and slows
tumor growth in a rabbit VX2 carcinoma model [22].
Volociximab, however, does not cross-react with rodent
α5β1, precluding its use in standard mouse xenograft
models of cancer. Although commercially available anti-
bodies against mouse α5 exist, we and others have found
that these monoclonals do not elicit cell death or inhibit
tumor progression in vivo [23,24].
To determine whether blockade of α5β1 in murine dis-
ease models results in inhibition of angiogenesis and
tumor growth, we sought to generate a function blocking
antibody that closely mirrored the known properties of
volociximab. To this end, we generated a panel of rat-anti-
mouse integrin α5β1 antibodies and subjected them to a
rigorous screening strategy designed to identify antibodies
that reproduce the known properties of volociximab that
are associated with its efficacy in vitro and in vivo.
Methods
Purification of mouse placental α5β1
Mouse placental integrin α5β1 was purified by affinity
chromotagraphy using rat anti-mouse α5β1 antibody
BMC5 (Chemicon) essentially as described [25]. Briefly,
antibody was coupled to CNBr-coupled Sepharose (Phar-
macia) and mouse placenta was homogenized using a
Polytron tissue homogenizer in lysis buffer [200 mM
octyl-β-gluocopyranoside, 1 mM phenylmethylsulfonyl
fluoride, 1 mM MgCl2, 0.5 mM CaCl2, 150 mM NaCl, 25
mM HEPES (pH 7.0)], followed by incubation on ice.
After centrifugation, the cleared lysate was loaded onto a
BMC5-Sepharose column and washed with 20 column
volumes of lysis buffer with the octyl-β-gluocopyranoside
substituted with 0.1% Nonidet P-40. Integrin was eluted
at low pH in a buffer containing 10 mM EDTA and dia-
lyzed against phosphate buffered saline.
Cloning of mouse integrin and purification of α5β1-Fc 
fusion protein
Total RNA (1 µg) isolated from mouse tissue was solubi-
lized in Trizol™ (Invitrogen) and cDNA was produced
using SuperScript II (Invitrogen). Full-length α5 and β1
were amplified by PCR using gene-specific primers (Qia-
gen N.V.). PCR products were subcloned into the pCR4
TOPO vector (Invitrogen) and verified by sequencing. To
generate the α5 and β1-Fc fusion genes, regions encoding
the extracellular domains of the α5 and β1 integrin genes
were isolated by restriction digest and individually sub-
cloned into the expression vector DEF38 (ICOS) to create
an in-frame fusion between each of the extracellular
domains and the constant region of the human γ1 immu-
noglobulin heavy chain gene. A stable cell line was gener-
ated by co-transfecting 293 cells with a 50:50 mix of α5-
Fc and β1-Fc plasmid DNAs using FuGene (Roche). Con-
ditioned medium was harvested and Fc fusion protein was
purified by standard methods using Protein G Sepharose.Journal of Translational Medicine 2007, 5:61 http://www.translational-medicine.com/content/5/1/61
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Generation of anti-mouse integrin α5β1 antibodies
Female Sprague-Dawley rats (Simonsen) were immunized
intraperitoneally with α5β1 purified from mouse placenta
or with a mouse α5β1-Fc fusion protein. Monoclonal
antibodies were generated by standard techniques fusing
spleen cells from immunized mice with an NSO-derived
fusion partner (American Type Culture Collection). A
panel of α5β1-specific antibodies was identified by ELISA
using the Fc-fusion protein and by flow cytometry analysis
of binding to mouse endothelial cells and cell lines.
Integrin α5β1 binding ELISA
Purified α5β1-Fc (100 ng) was plated into wells in 50 mM
Na2CO3 (pH 8.6), 0.5 mM each of CaCl2, MgCl2, and
MnCl2 at 4°C overnight. Plates were blocked with 5% BSA
in PBS for 1 hr with shaking. Following washes in PBS
with 0.05% Tween-20, wells were incubated for 1 hr with
serial dilutions of candidate antibodies or control rat IgG
(Jackson ImmunoResearch) in 1% BSA in PBS with 0.05%
Tween-20. Wells were then washed and incubated with
100 µL/well of the goat anti-rat IgG-HRP (1:5,000) for 1
hr. Washed plates were incubated with TMB substrate
(Sigma), developed with 650 Stop Reagent (BioFX), and
read at A650.
Fibronectin binding inhibition ELISA
Cellular mouse fibronectin-coated plates (250 ng in coat-
ing buffer overnight at 4°C) were washed with PBS con-
taining 0.05% Tween-20, and blocked as described above.
Plates were incubated with α5β1-Fc fusion protein in the
presence of various concentrations of the indicated anti-
bodies for 1 hr at room temperature. Following 2 washes,
plates were further incubated with goat anti-human IgG
Fc-HRP (1:5000; Jackson ImmunoResearch) at room tem-
perature for 1 hr. Plates were then washed 5 times and
incubated with TMB substrate, developed, and read at
A650.
Flow cytometry
Cells were removed with 20 mM EDTA in Tris-HCl (pH
8.0) and blocked by centrifugation in HBSS containing
3% heat-inactivated FBS, 1% normal goat serum (Sigma)
and 1% BSA at 4°C for 5 min. Cells were incubated for 1
hr at 4°C with the indicated supernatant or antibody (10
µg/mL) in FACS buffer (PBS containing 0.1% BSA). Excess
mAb was removed by centrifugation and cells were resus-
pended in FACS buffer containing anti-rat IgG-PE second-
ary antibody (Southern Biotech). After an additional
wash, fluorescence intensity was measured on a FACSCal-
ibur flow cytometer (Becton Dickinson).
Migration assay
BD HTS FluoroBlok 96-well plates (top plate) were coated
with mouse plasma fibronectin (10 µg/ml; Upstate) in
PBS and air-dried. 200 µl migration medium (MM; RPMI
+ 0.1% BSA) with or without antibody was dispensed into
a BD Falcon 96-Square Well Flat Bottom Assay plate (bot-
tom plates) and 10,000 cells/well in 50 µl was added to
the top plate in MM. After lowering the top plate into the
lower plate, cells were incubated at 37°C at 5% CO2 for 4
hr. Cells were stained with 2 µM Calcien-AM (Invitrogen)
in MM and visualized using the Discovery-1 High Content
Screening System (Molecular Devices).
Surface plasmon resonance
Affinities between α5β1-Fc and anti-integrin antibodies
were analyzed using a BIAcore 3000 essentially as
described [26,27]. Goat anti-rat Fc antibodies were immo-
bilized on a Research Grade CM5 chip using an amine
coupling kit (BIAcore). Rat-anti-mouse α5β1 antibodies
were captured onto goat anti-rat Fc surfaces, followed by
injection of mouse α5β1 in running buffer [(10 mM HBS,
2 mM CaCl2, 1 mM MnCl2, 700 mM NaCl (pH 7.4)] at a
flow rate of 30 µL/min at 25°C. Association phase
occurred over 3 min and dissociation over 1.5 hr. Kinetics
of binding was calculated from data at 6 different concen-
trations of analyte (512 nM, 128 nM, 32 nM, 8 nM, 2 nM,
0.5 nM), using the BIAevaluation program. Each goat
anti-rat Fc surface was regenerated at the end of each cycle
by a quick injection of 30 mM HCl. Double-referencing
was applied to eliminate responses from the reference sur-
face and buffer-only control. Affinity constant (KD) was
obtained by simultaneously fitting the association and
dissociation phases of the sensorgram from the analyte
concentration series using the 1:1 Langmuir model from
the BIAevaluate software.
Annexin V cell death assay
Primary mouse endothelial cells were incubated with anti-
mouse α5β1 antibodies at 10 µg/ml for 16 hr, after which
cell membrane phosphatidylserine was detected using
Oregon Green 488 conjugated Annexin V. Harvested cells
were washed with Annexin binding buffer [(ABB; 10 mM
HEPES, 140 mM NaCl, 2.5 mM CaCl2 (pH 7.4]) and incu-
bated in ABB (100 µl) containing Annexin V (10 µl). Fol-
lowing washing, cells were suspended in ABB containing
0.5 µg/mL propidium iodide (200 µl) and assessed by
flow cytometry.
HUVEC and murine EC in vitro angiogenesis models
HUVEC or murine lung EC's (5 × 105 cells/ml) were
seeded in Hank's balanced salt solution (HBSS) contain-
ing 3 mg/ml fibrinogen and 200 µg/ml aprotinin (Roche)
at 37°C, as described previously [21]. For each condition,
EC/fibrinogen/aprotinin mixture (500 µL) was quickly
transferred to a 24-well tissue culture plate containing α-
thrombin (1 U) and gently mixed. The resulting fibrin
matrices were polymerized at 37°C for 20 min. Antibody
was added in Medium 200 [1 ml, without LSGS and con-
taining 20% human or mouse serum (Rockland Immun-Journal of Translational Medicine 2007, 5:61 http://www.translational-medicine.com/content/5/1/61
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ochemicals), and rhTGF-α (0.01 µg/ml), rhHGF (0.1 µg/
ml) and rhVEGF and/or rmVEGF (0.1 µg/ml)]. Tubes
formed over 6 days, with one medium change (Medium
200 plus serum only) at day 3. For visualization of tubes,
matrices were fixed with 4% formaldehyde for 4 hr and
stained overnight with 1 ml phalloidin-Alexa 488 (1.75
U/ml) in 50% fetal calf serum (FCS) containing 0.25%
saponin. Vessel formation was visualized using the Dis-
covery-1 High Content Screening System (Molecular
Devices) and quantified using the accompanying soft-
ware.
Immunohistochemistry
Xenograft tumors derived from cells inoculated subcuta-
neously in ICR-SCID or SCID-Beige mice (Taconic Farms)
were frozen in OCT compound and stored at -70°C. Cry-
ostat tissue sections (4-5 µm) were fixed in acetone for 10
min, air dried and incubated in 0.03% H2O2 for 10 min.
After successive incubations with Avidin block, Biotin
block and Protein block solutions for 15 min each, sam-
ples were treated with the indicated antibodies or biotin-
conjugated rat anti-mouse CD31 mAb MEC 13.3 or
biotin-conjugated IgG2a isotype control (2.5 µg/ml; BD
Pharmingen) for 60 min. Sections were developed using
the Vectastain Elite ABC kit (Vector Laboratories) and sta-
ble diaminobenzidine (Dako). All staining procedures
were performed using a Dako Autostainer at room tem-
perature.
In vivo xenograft studies
Six- to eight-week-old ICR SCID or SCID-Beige female
mice, obtained from Taconic Farms and maintained in
micro-isolator cages, received subcutaneous injections on
the right flank of 5 × 106 A673 human rhabdomyosar-
coma or 1 × 107 SVR murine angiosarcoma cells. Tumors
were allowed to establish for 7–18 days, reaching an aver-
age of 50–100 mm3, as determined by caliper measure-
ment. Animals were distributed into groups of ten and
received vehicle (PBS) or rat anti-mouse integrin α5β1
antibody (200 µl at 1.0 mg/ml). Reagents were delivered
by intraperatoneal injection twice or thrice weekly for the
duration of the studies. Tumor volume was measured
twice weekly, and clinical and mortality observations were
performed daily according to Institutional Animal Care
and Use Committee regulations.
Results
Generation and characterization of rat anti-mouse 
integrin α5β1 antibodies
To generate antibodies directed against murine integrin
α5β1, Sprague-Dawley rats were immunized with mouse
α5β1-Fc fusion protein or with affinity-purified integrin
from mouse placenta. Supernatants from the resulting
hybridomas were subjected to a number of assays
designed to identify clones that produced antibodies
encompassing characteristics that define volociximab,
including heterodimer specificity, blocking activity, high
affinity binding to the Fc fusion protein and binding to
endothelial cells [21]. Over sixty clones were screened for
these functional properties.
Selected antibodies represented a range of binding charac-
teristics. These included antibodies specific for α5, β1 or
α5β1 heterodimer, as determined by ELISA (Figure 1A),
and spanned a range of relative affinities (Figure 1B) and
abilities to block binding of α5β1 to fibronectin (Figure
1C). Interestingly, one antibody, 321.1, increased binding
of integrin to fibronectin, suggesting that it may recognize
a ligand-induced binding site (LIBS). In general, most α5-
,  β1- and α5β1 heterodimer-specific antibodies recog-
nized integrin α5β1 on immortalized endothelial cells
(Figure 1D). Taken together these assays identified a
number of antibodies that resemble volociximab in vitro.
Cross-reactivity assays
Volociximab does not bind to murine α5β1 [22], suggest-
ing that differences exist in this critical functional epitope
between mice and humans. A number of antibodies were
cross-reactive for human integrin, including a majority of
the  α5 and heterodimer specific antibodies and all of
those tested that bound β1 (Figure 2A). Immunohisto-
chemical analysis of sections from human α5β1 positive
(MDA-MB-231) and negative (C32) xenograft tumors fur-
ther confirmed that antibodies that cross-reacted to
human integrin by ELISA also did so on tissue sections
(Figure 2B). For example, 517-2, which cross-reacts by
ELISA, binds to tumor cells in the α5β1 positive MDA-
MB-231 xenograft, and not to C32 xenograft tumor cells,
but binds to murine α5β1 on the vasculature and stroma
of both xenografts. Antibody 339.1, on the other hand,
does not cross-react to human integrin by ELISA and does
not bind tumor cells in either the MDA-MB-231 or the
C32 xenograft, yet it recognizes murine α5β1 on vessels
and stroma. The panel of antibodies, therefore, represents
antibodies that bind human α5β1 and those that do not.
Migration assays
High affinity, function-blocking antibodies against
integrin α5β1 have been reported to inhibit endothelial
cell migration and tube formation and elicit cell death in
vitro [15,16,21]. A subset of antibodies from the panel was
assessed for these effects in murine cell-based assays. Inhi-
bition of migration towards fibronectin was determined
using the murine hemangioma line SVEC. Of the antibod-
ies tested, 13E9-20, 517-2 and 339.1 were among the
most potent (Figure 3A, B), each inhibiting migration by
greater than 50% relative to an IgG control. The extent of
inhibition for each antibody was statistically significant (p
< 0.05) relative to control.Journal of Translational Medicine 2007, 5:61 http://www.translational-medicine.com/content/5/1/61
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BIAcore analysis
Volociximab has a very high affinity for human α5β1 [21].
We were therefore interested in identifying antibodies
with similarly high affinity for mouse α5β1. Selected anti-
bodies were purified from supernatants using Protein A
affinity chromatography and assessed for binding to
mouse and human α5β1 by BIAcore. Of the human cross-
reactive set, 517-2 had the highest affinity (KD = 0.21 nM)
and of the non-cross-reactive set, antibody 339.1 bound
tightest (KD = 0.59 nM). The affinities of both antibodies
were sub-nanomolar, comparing favorably with volocixi-
mab (KD = 0.32 nM).
Cell death assays
The highest affinity antibodies that inhibited α5β1 bind-
ing to fibronectin and cell migration, were human cross-
reactive antibody 517-2 and mouse-specific antibody
339.1. These two antibodies, and a third, lower affinity
antibody (KD = 11.5 nM) that binds both mouse and
human integrin, 13E9-20, were assessed for their ability to
elicit cell death in mouse ECs in a manner analogous to
that of volociximab on HUVEC. Primary murine endothe-
lial cells were incubated with the antibodies for 16 hours
and Annexin V binding was assessed by flow cytometry.
339.1 induced significant apoptosis in these cells whereas
517-2 and 13E9-20 did not, despite 517-2 and 339.1 hav-
ing similar affinities for mouse integrin (Figure 4A). 339.1
also induced cell death in the T-antigen transformed
Representative hybridoma screening results Figure 1
Representative hybridoma screening results. Hybridoma supernatants were compared by ELISA for binding to murine 
α5β1-Fc heterodimer, α5-Fc or β1-Fc homodimer or an irrelevant Fc fusion protein, (A). Hybridomas were found to produce 
antibodies with specific preferences for each protein. Supernatants were further tested for binding to murine EC's by flow 
cytometry, (B). The majority of antibodies tested recognized cell surface integrin. Antibodies purified from supernatants that 
recognized murine EC's by flow cytometry and showed a preference for α5β1 heterodimer were compared for their capacity 
to inhibit the binding of α5β1-Fc to mouse fibronectin by competitive ELISA, (C). Many antibodies inhibited integrin-fibronectin 
binding; one antibody, 321.1, was found to promote binding. Antibodies were assessed for binding to cellular integrin α5β1 on 
SVR cells by flow cytometry, (D). Most of the antibodies that bound integrin α5β1 by ELISA also bind cell surface integrin in 
vitro.
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Testing antibody cross-reactivity to human α5β1 Figure 2
Testing antibody cross-reactivity to human α5β1. Representative antibodies were compared by ELISA for binding to 
human and murine α5β1-Fc or irrelevant Fc fusion proteins, (A). A subset of competitive antibodies cross-reacted with human 
integrin. Antibodies were tested by immunohistochemistry for staining of sections from C32 melanoma (α5β1 negative) or 
MDA-MB-231 breast carcinoma (α5β1 positive) xenografts, (B). The majority of antibodies tested stained murine α5β1 on 
tumor vasculature, but only antibodies found to cross-react with human α5β1 by ELISA specifically stained MDA-MB-231 
xenograft cells as well. IIA1, the mouse parent antibody of volociximab, which recognizes only human integrin, anti-mouse 
CD31, which stains mouse vessels, and pooled rat IgG are shown as controls.
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murine endothelial cell line SVR, with an EC50 of 5.3 nM
(Figure 4B), compared to an EC50 of 2.5 nM for volocixi-
mab on HUVEC. This finding suggests that although
339.1 and 517-2 have similar biological capabilities and
similar affinities, initiation of the cell death program
requires binding to a highly specific epitope, specifically
recognized by 339.1.
Tube formation assays
To determine if 339.1 also inhibited the formation of cap-
illary-like structures in an in vitro angiogenesis assay,
endothelial cells isolated from mouse lungs were induced
to form tubes in a fibrin matrix in the presence or absence
of antibody. Antibody 339.1 significantly inhibited tube
formation (Figure 5A, B; p = 0.018), although this activity
was not as robust as the inhibitory effects exerted by the
human cross-reactive antibodies or volociximab on
HUVEC tube formation (data not shown; [21]). This sug-
gests that murine lung microvascular cells are less sensi-
tive, in general, to anti-α5β1 activity, relative to human
umbilical vein endothelial cells, in this assay. Neverthe-
less, these results demonstrate that antibodies in this
panel can inhibit the ability of mouse and human
endothelial cells to adopt a vessel-like structure in a three
dimensional assay.
Xenograft experiments
Antibodies against human α5β1, including volociximab,
inhibit angiogenesis and impede tumor growth in vivo
[21,22]. As volociximab does not cross-react with rodent
integrin, these earlier studies were conducted in rabbit
and monkey models. We therefore considered whether
339.1 affects tumor growth in syngeneic and xenograft
tumor models. In the murine endothelial-derived angi-
osarcoma model, SVR, 339.1 targets both tumor and
tumor vascular endothelial cells. 339.1, administered
intraperitoneally to mice bearing established tumors,
thrice weekly at 10 mg/kg, inhibited tumor growth by
approximately 60% (p = 0.007; Figure 6A). In the A673
human xenograft model, 339.1 targets vascular endothe-
lial cells, but not tumor cells. 339.1 inhibited tumor
growth in these models by approximately 40% relative to
tumors from control-treated mice (p = 0.022; Figure 6B).
As in the C32 and MDA-MB-231 xenografts, vessels
stained positive for integrin with 339.1 in both of these
xenograft models (data not shown). Sections from A673
tumors treated with 339.1 were assessed for vessel density
by immunohistochemistry using an antibody against anti-
CD31 (Figure 6C). Vascular density was significantly
decreased in tumors from treated animals compared to
tumors that received vehicle (p = 0.011; Figure 6D); statis-
tically significant results were obtained in a second exper-
iment employing 25 mg/kg 339.1 three times weekly (15
animals per group; 47% inhibition, p < 0.001), whereas
two additional experiments utilizing the 25 mg/kg dosing
schedule did not show significant effects (5 animals per
group each; 1%, p = 0.96 and 10%, p = 0.82). These results
confirm that 339.1, like volociximab, impedes tumor
growth, at least in part, by inhibiting angiogenesis.
Discussion
The strategy of targeting angiogenesis to inhibit cancer
progression has received increasing attention in recent
years. Despite the recent approval of targeted therapies in
this area, optimizing the use of anti-angiogenic drugs in
the clinic has been difficult. Challenges that face anti-ang-
iogenic agents that are currently under development
include choosing disease areas that might benefit most,
optimizing combination strategies with existing standards
of care and defining patient populations that might
respond best to therapy. Preclinical models of disease pro-
vide the best opportunity for addressing these issues,
Cell migration assays Figure 3
Cell migration assays. Immortalized murine endothelial 
SVEC-4 cells, (A), were assessed for chemotaxis to fibronec-
tin coated on the opposite side of transwell membranes in 
the presence or absence of anti-integrin antibodies. Cells 
were stained with Calcein AM and visualized by fluorescence 
microscopy. Migration in quintiplicate wells was quantified 
using the Discovery-1 system, (B). Antibodies that inhibited 
binding of α5β1 binding to fibronectin also inhibited migra-
tion towards fibronectin.
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therefore appropriate reagents for use in these systems are
essential for driving drugs through development.
Volociximab has been shown to inhibit the growth of new
blood vessels in preclinical models of ocular angiogenesis
[21]. This effect was found to translate into decreased
tumor growth in the rabbit VX2 carcinoma model [22].
These experiments provided a strong proof of concept
demonstration of volociximab activity in vivo and defined
a novel mechanism of action for angiogenesis inhibition.
However, the VX2 model is limited in that it represents a
very aggressive tumor, must be passaged in vivo, is carried
out in immunocompetent animals (resulting in antibody
clearance) and requires large amounts of antibody. To fur-
ther define volociximab mechanism of action and identify
appropriate settings for its use in tractable animal models
of cancer, it was therefore imperative a similar reagent
with activity in mouse be generated.
A number of antibodies against mouse α5β1 are available
commercially. We have found that although some of
these antibodies inhibit binding of α5β1 to fibronectin,
none inhibited other biological functions, such as migra-
tion, in vitro angiogenesis or tumor growth in vivo (unpub-
lished observations; [23,24]). However, the α5 knockout
mouse is embryonically lethal due to gross defects in vas-
cular architecture [28], suggesting that in mice, as in
humans, α5β1 is important for blood vessel formation
and/or integrity. The new panel of reagents described
herein represents a number of α5- and β1-specific anti-
bodies. Of note, Fc-fusion protein-based immunizations
resulted in a higher proportion of α5-specific antibodies,
whereas placenta-based immunization resulted in a
higher proportion of heterodimer-specific antibodies,
including 339.1 (data not shown). As the overall number
of antibodies produced by each method was similar, this
suggests that the purified material may have resulted in
similar immunogenicity while maintaining a more native
In vitro angiogenesis assays Figure 5
In vitro angiogenesis assays. Primary endothelial cells iso-
lated from mouse lung were induced to form tubes in a 
three-dimensional fibrin matrix under the influence of 
growth factors, in the presence of 339.1 or control IgG, (A). 
Results from triplicate wells were quantified using the Dis-
covery-1 system (B). Inclusion of 339.1 in this assay results in 
a decrease in tube formation.
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Annexin V cell death assays Figure 4
Annexin V cell death assays. Primary mouse endothelial cells were incubated with 339.1, 517-2 or 13E9-20 (10 µg/ml) for 
16 hours and assessed for Annexin V-Alexa Fluor 488 binding by flow cytometry. Cells were counterstained with propidium 
iodide (PI) to follow non-specific death and the percentage of cells that stained positive for Annexin V and negative for PI was 
plotted. Representative results from three individual experiments are shown, (A). Only antibody 339.1, which does not cross-
react with human α5β1, elicited cell death in these cells. A dose response curve for 339.1 in this assay using SVR murine angi-
osarcoma cells revealed an EC50 of 5.3 nM, (A).
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quaternary structure in vivo. In either case, many of the
antibodies that bound α5 or were specific for α5β1 het-
erodimer blocked binding to fibronectin and competed,
at least in part, with one another in ELISA or FACS assays
(data not shown). Of these antibodies, one group cross-
reacted with human integrin, while another did not, sug-
gesting that at least two distinct epitopes were repre-
sented. This implies that inhibition of binding to
fibronectin can be achieved through blocking at multiple
sites, possibly through steric hindrance. Importantly, not
all antibodies that block binding to fibronectin have
equivalent biological function in vitro or in vivo. 517-2 and
339.1, for example, each bind with high affinity (0.21 nM
and 0.59 nM, respectively) block binding to fibronectin
and inhibit migration. Moreover, both antibodies have rat
IgG1 constant regions, which like volociximab, a human
IgG4, would be predicted to lack significant effector activ-
ity. However, only 339.1, which does not cross-react with
human  α5β1, elicits significant cell death in vitro and
inhibits angiogenesis and tumor progression in vivo. This
339.1 inhibits angiogenesis and tumor growth in vivo Figure 6
339.1 inhibits angiogenesis and tumor growth in vivo. Mice bearing established SVR murine angiosarcoma, (A) or A673 
human rhabdomyosarcoma tumors, (B), were treated with 339.1 (10 mg/kg, intraperitoneally, thrice or twice weekly, respec-
tively) or vehicle control and tumor volume was monitored using vernier calipers. 339.1 inhibits tumor growth in vivo relative 
to control. Results were statistically significant in both settings. A673 tumors were resected from 339.1- and control-treated 
mice and frozen sections were assessed for vessel density by immunohistochemical staining for CD31, (C). Vessel density was 
significantly reduced in tumors from animals treated with 339.1, (D).Journal of Translational Medicine 2007, 5:61 http://www.translational-medicine.com/content/5/1/61
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finding suggests that although these antibodies have sim-
ilar biological functionality and similar affinities, initia-
tion of the cell death program requires binding to a highly
specific epitope. This result also suggests that 339.1 binds
to the murine cognate of the epitope recognized by
volociximab, which would be predicted to be non-homol-
ogous between mouse and human α5β1, since volocixi-
mab does not cross-react with mouse integrin. A corollary
of this hypothesis is that an antibody that recognizes both
human and mouse integrin would not bind this impor-
tant epitope, and therefore might not elicit cell death, as is
the case with 517-2.
339.1 inhibits tumor growth in an A673 rhabdosarcoma
model. This model was chosen to evaluate anti-α5β1
activity because it was reported to be sensitive to the
mouse parent antibody of bevacizumab, A.4.6.1, suggest-
ing that its growth is highly dependent on angiogenesis
[8]. However, A.4.6.1 and bevacizumab do not inhibit
tumor growth in other xenograft models to the same
extent as in the A673 model [29,30]. The reasons for this
are not fully understood; 339.1 is currently being evalu-
ated in additional xenograft models to determine if simi-
lar differences in sensitivities are observed with this
antibody. Comparing xenograft models that respond to
339.1 to varying degrees may reveal molecular mecha-
nisms that will help stratify patients and illuminate com-
bination strategies that might best slow disease
progression. In addition, the combination of 339.1 and
volociximab is currently being assessed in xenograft mod-
els to determine the effect of targeting both tumor and
host α5β1 in vivo.
Conclusion
The results described in this report represent the first
description of a mouse-specific α5β1 inhibitor that blocks
EC function, angiogenesis and tumor growth in vivo.
These results demonstrate that blocking α5β1 function in
mouse models results in an inhibition of tumor growth
through a decrease in vessel density. The identification
and characterization of anti-α5β1 antibody 339.1 will
facilitate further exploration of α5β1 function and the
utility of integrin blocking strategies in disease.
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